


# Why A Network Approach?

Marty Tenenbaum

April 2, 2015

# Precision Oncology 3.0



- Molecular tumor boards
- Omics / laboratory
- Data analysis and informatics
- Validation (in vitro, in vivo, in silico)
- Drug access
- Reimbursement
- CRO

**Services can be provided by the network operator, other LaRCs, or third parties.**

# Scale – Network of LaRCs

- **Patients**
  - Case volume
  - Local access to care
  - Interest to physicians, researchers, pharma....
- **Staffing**
- **Economies of scale (e.g., insurance, platforms for omics, drug screens), drug access and reimbursement)**
- **Funding for Marketing, PR, R&D, software development, lobbying...**
- **N-of-1 studies, clinical trials...**
- **Investment opportunities (VCs, equity markets)**

- Patient recruiting
- Marketing and PR
- Business development (clinics, service providers, partnerships with pharma / biotech and payers, IP licensing)
  - Franchise members' services
- Informatics (data- and knowledge bases, case reports, specimen repositories, decision support tools, rapid learning...)
- Virtual Molecular Tumor Boards
- R&D, software development / integration (platform)
- CRO functions: clinical trials, point of care studies, clinical validations
  - New models of cancer research and drug development.
- Rules of engagement (e.g., SOPs, data and specimen sharing), governance
- Lobbying

- **Single LaRC plus networked ecosystem**
  - LaRC can be both a consumer and provider of services
- **Network of collaborating LaRCs**
  - LaRCs can be centrally owned, franchised, or independent
  - At least one under common control with the Network, to ensure the ability to try experimental treatments
  - Independent LaRCs can be affiliated with institutions
  - Let a 1000 'LaRC business models' bloom!
- **Network independently owned and operated**
  - For profit, non-profit, or public benefit corporation
  - Virtual MTB free to pursue best available treatments.
  - Catalyze a movement to beat cancer

# Rapid Learning Network



**George Demetri**  
Dana Farber



**Tony Blau**  
U. Wash.



**Eric Schadt**  
Mt. Sinai



**Mitesh Borad**  
Mayo Clinic



**Lincoln Nadauld**  
Intermountain Health



**Andrea Califano**  
Columbia U.



RESPONSE GENETICS

Genomic Health  
LIFE. CHANGING.

CHAMPIONS  
ONCOLOGY

GENEKEY

RARECYTE  
One in a billion

GUARDANT HEALTH



**Joel Neal**  
Stanford



**Beth Karlan**  
Cedars Sinai



**Ravi Salgia**  
U. Chicago



**Keith Flaherty**  
MGH



**Heinz Josef Lenz, USC**



# CancerCommons

[jmt@cancercommons.org](mailto:jmt@cancercommons.org)

**(650) 799 1767**